A major obstacle to successful bone marrow transplants (BMT) is rejection due to the age discrepancy of the donor and recipient, with older donors presenting problems due to the donor stem cells’ loss of efficacy with age. The older stem cells’ compromised ability to actively regenerate (given that older stem cells are less active than younger stem cells) increases the risk of age-related rejection significantly. In a groundbreaking study, researchers have discovered that the in-vitro (outside the body) introduction of young mesenchymal stem cells (MSCs) to aged donor hematopoietic stem cells (HSCs) used for transplants resulted in the rejuvenation of the donor cells likely improving the efficacy of the transplant.
This study is pivotal in expanding accessibility to bone marrow donors that are suitable matches, without having the need to worry about rejection due to discrepancy in donor and recipient ages. By expanding the pool of available donors through hematopoietic stem cell rejuvenation, lifesaving transplants could become available for thousands of patients on waiting lists.
This innovative research demonstrates the integral role stem cells are playing in cutting edge medical care options, as well as the wisdom of banking stem cells as young as possible. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.